Erik Fink Eriksen

  • Professor II
  • +47 228 94187

Publications 2022

Bjerkreim BA, Hammerstad SS, Gulseth HL, Berg TJ, Lee-Ødegård S, Eriksen EF (2022)
Thyroid Signaling Biomarkers in Female Symptomatic Hypothyroid Patients on Liothyronine versus Levothyroxine Monotherapy: A Randomized Crossover Trial
J Thyroid Res, 2022, 6423023
DOI 10.1155/2022/6423023, PubMed 35572853

Bjerkreim BA, Hammerstad SS, Gulseth HL, Berg TJ, Omdal LJ, Lee-Ødegård S, Eriksen EF (2022)
Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study
Front Endocrinol (Lausanne), 13, 816566
DOI 10.3389/fendo.2022.816566, PubMed 35273566

Publications 2021

Bjerkreim BA, Hammerstad SS, Gulseth HL, Berg TJ, Lee-Ødegård S, Rangberg A, Jonassen CM, Budge H, Morris D, Law J, Symonds M, Eriksen EF (2021)
Effect of Liothyronine Treatment on Dermal Temperature and Activation of Brown Adipose Tissue in Female Hypothyroid Patients: A Randomized Crossover Study
Front Endocrinol (Lausanne), 12, 785175
DOI 10.3389/fendo.2021.785175, PubMed 34867829

Borgen TT, Eriksen EF (2021)
Bone turnover markers in the treatment of osteoporosis
Tidsskr Nor Laegeforen, 141 (17)
DOI 10.4045/tidsskr.21.0119, PubMed 34813213

Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P (2021)
Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial
J Bone Miner Res, 37 (1), 36-40
DOI 10.1002/jbmr.4457, PubMed 34633116

Eriksen EF, Lech O, Nakama GY, O'Gorman DM (2021)
Disease-Modifying Adjunctive Therapy (DMAT) in Osteoarthritis-The Biological Effects of a Multi-Mineral Complex, LithoLexal® Joint-A Review
Clin Pract, 11 (4), 901-913
DOI 10.3390/clinpract11040104, PubMed 34940003

Syversen U, Mosti MP, Mynarek IM, Vedal TSJ, Aasarød K, Basso T, Reseland JE, Thorsby PM, Asvold BO, Eriksen EF, Stunes AK (2021)
Evidence of impaired bone quality in men with type 1 diabetes: a cross-sectional study
Endocr Connect, 10 (8), 955-964
DOI 10.1530/EC-21-0193, PubMed 34289447

Publications 2020

Eriksen EF, Shabestari M, Ghouri A, Conaghan PG (2020)
Bisphosphonates as a treatment modality in osteoarthritis
Bone, 143, 115352
DOI 10.1016/j.bone.2020.115352, PubMed 32247817

Hewitt S, Kristinsson J, Aasheim ET, Blom-Høgestøl IK, Aaseth E, Jahnsen J, Eriksen EF, Mala T (2020)
Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study
Obes Surg, 30 (9), 3426-3434
DOI 10.1007/s11695-020-04582-5, PubMed 32306297

Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF (2020)
Bone, 137, 115390
DOI 10.1016/j.bone.2020.115390, PubMed 32353565

Rubin KH, Möller S, Choudhury A, Zorina O, Kalsekar S, Eriksen EF, Andersen M, Abrahamsen B (2020)
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries
Bone, 134, 115296
DOI 10.1016/j.bone.2020.115296, PubMed 32097760

Shabestari M, Shabestari YR, Landin MA, Pepaj M, Cleland TP, Reseland JE, Eriksen EF (2020)
Altered protein levels in bone marrow lesions of hip osteoarthritis: Analysis by proteomics and multiplex immunoassays
Int J Rheum Dis, 23 (6), 788-799
DOI 10.1111/1756-185X.13843, PubMed 32383346

Publications 2019

Blom-Høgestøl IK, Hewitt S, Chahal-Kummen M, Brunborg C, Gulseth HL, Kristinsson JA, Eriksen EF, Mala T (2019)
Bone metabolism, bone mineral density and low-energy fractures 10 years after Roux-en-Y gastric bypass
Bone, 127, 436-445
DOI 10.1016/j.bone.2019.07.014, PubMed 31323430

Blom-Høgestøl IK, Mala T, Kristinsson JA, Hauge EM, Brunborg C, Gulseth HL, Eriksen EF (2019)
Changes in Bone Marrow Adipose Tissue One Year After Roux-en-Y Gastric Bypass: A Prospective Cohort Study
J Bone Miner Res, 34 (10), 1815-1823
DOI 10.1002/jbmr.3814, PubMed 31216081

Borgen TT, Bjørnerem Å, Solberg LB, Andreasen C, Brunborg C, Stenbro MB, Hübschle LM, Froholdt A, Figved W, Apalset EM, Gjertsen JE, Basso T, Lund I, Hansen AK, Stutzer JM, Dahl C, Omsland TK, Nordsletten L, Frihagen F, Eriksen EF (2019)
High prevalence of vertebral fractures and low trabecular bone score in patients with fragility fractures: A cross-sectional sub-study of NoFRACT
Bone, 122, 14-21
DOI 10.1016/j.bone.2019.02.008, PubMed 30743015

Borgen TT, Bjørnerem Å, Solberg LB, Andreasen C, Brunborg C, Stenbro MB, Hübschle LM, Froholdt A, Figved W, Apalset EM, Gjertsen JE, Basso T, Lund I, Hansen AK, Stutzer JM, Omsland TK, Nordsletten L, Frihagen F, Eriksen EF (2019)
Post-fracture Risk Assessment: Target the Centrally Sited Fractures First! A Substudy of NoFRACT
J Bone Miner Res, 34 (11), 2036-2044
DOI 10.1002/jbmr.3827, PubMed 31310352

Zebaze R, Osima M, Bui M, Lukic M, Wang X, Ghasem-Zadeh A, Eriksen EF, Vais A, Shore-Lorenti C, Ebeling PR, Seeman E, Bjørnerem Å (2019)
Adding Marrow Adiposity and Cortical Porosity to Femoral Neck Areal Bone Mineral Density Improves the Discrimination of Women With Nonvertebral Fractures From Controls
J Bone Miner Res, 34 (8), 1451-1460
DOI 10.1002/jbmr.3721, PubMed 30883870

Publications 2018

Andreasen C, Solberg LB, Basso T, Borgen TT, Dahl C, Wisløff T, Hagen G, Apalset EM, Gjertsen JE, Figved W, Hübschle LM, Stutzer JM, Elvenes J, Joakimsen RM, Syversen U, Eriksen EF, Nordsletten L, Frihagen F, Omsland TK, Bjørnerem Å (2018)
Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture Among Patients With a Fragility Fracture in the Norwegian Capture the Fracture Initiative (NoFRACT): A Trial Protocol
JAMA Netw Open, 1 (8), e185701
DOI 10.1001/jamanetworkopen.2018.5701, PubMed 30646281

Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M (2018)
Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Bone, 120, 1-8
DOI 10.1016/j.bone.2018.09.020, PubMed 30268814

Eriksen EF, Moen MH, Iversen OE (2018)
[Estrogens in menopause – time to change the guidelines?]
Tidsskr Nor Laegeforen, 138 (6)
DOI 10.4045/tidsskr.17.1059, PubMed 29557135

Eriksen EF, Moen MTHS, Iversen OE (2018)
Oestrogens in menopause- time to change the recommendations?
Tidsskr. Nor. Laegeforen., 138 (6), 532-534

Hewitt S, Aasheim ET, Søvik TT, Jahnsen J, Kristinsson J, Eriksen EF, Mala T (2018)
Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery
Clin Endocrinol (Oxf), 88 (3), 372-379
DOI 10.1111/cen.13531, PubMed 29235126

Paschalis EP, Krege JH, Gamsjaeger S, Eriksen EF, Burr DB, Disch DP, Stepan JJ, Fahrleitner-Pammer A, Klaushofer K, Marin F, Pavo I (2018)
Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques
J Bone Miner Res, 33 (12), 2230-2235
DOI 10.1002/jbmr.3565, PubMed 30102789

Rejnmark L, Brixen K, Kassem M, Hermann P, Vestergaard P, Eriksen EF, Bollerslev J, Nielsen HK, Charles P, Langdahl B (2018)
Leif Mosekilde IN MEMORIAM
J. Bone Miner. Res., 33 (11), 1913
DOI 10.1002/jbmr.3588

Publications 2017

Garcia Lopez M, Bønaa KH, Ebbing M, Eriksen EF, Gjesdal CG, Nygård O, Tell GS, Ueland PM, Meyer HE (2017)
B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials
J Bone Miner Res, 32 (10), 1981-1989
DOI 10.1002/jbmr.3189, PubMed 28574605

Gulseth HL, Wium C, Angel K, Eriksen EF, Birkeland KI (2017)
Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects With Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial
Diabetes Care, 40 (7), 872-878
DOI 10.2337/dc16-2302, PubMed 28468770

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE (2017)
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
J Bone Oncol, 7, 1-12
DOI 10.1016/j.jbo.2017.03.001, PubMed 28413771

Holmøy T, Lindstrøm JC, Eriksen EF, Steffensen LH, Kampman MT (2017)
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial
BMC Neurol, 17 (1), 67
DOI 10.1186/s12883-017-0851-0, PubMed 28376767

Osima M, Kral R, Borgen TT, Høgestøl IK, Joakimsen RM, Eriksen EF, Bjørnerem Å (2017)
Women with type 2 diabetes mellitus have lower cortical porosity of the proximal femoral shaft using low-resolution CT than nondiabetic women, and increasing glucose is associated with reduced cortical porosity
Bone, 97, 252-260
DOI 10.1016/j.bone.2017.01.037, PubMed 28161589

Shabestari M, Eriksen EF, Paschalis EP, Roschger P, Gamsjaeger S, Klaushofer K, Berzlanovich A, Nogues X, Puig L, Diez-Perez A (2017)
Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report
Bone Rep, 6, 81-86
DOI 10.1016/j.bonr.2017.02.006, PubMed 28377987

Sosa DD, Eriksen EF (2017)
Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study
Calcif Tissue Int, 101 (1), 34-42
DOI 10.1007/s00223-017-0256-5, PubMed 28246929

Steineger J, Merckoll E, Slåstad JM, Eriksen EF, Heimdal K, Dheyauldeen S (2017)
Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
Laryngoscope, 128 (3), 593-596
DOI 10.1002/lary.26722, PubMed 28671294

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Bone, 105, 11-17
DOI 10.1016/j.bone.2017.08.003, PubMed 28789921

Aass C, Norheim I, Eriksen EF, Børnick EC, Thorsby PM, Pepaj M (2017)
Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy
PLoS One, 12 (4), e0175274
DOI 10.1371/journal.pone.0175274, PubMed 28419103

Publications 2016

Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES (2016)
Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway
J Clin Endocrinol Metab, 101 (8), 3045-53
DOI 10.1210/jc.2016-1477, PubMed 27186861

Eriksen EF, Brown JP (2016)
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Bone, 86, 139-42
DOI 10.1016/j.bone.2016.02.009, PubMed 26944033

Eriksen EF, Brown JP (2016)
Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics"
Bone, 89, 75-76
DOI 10.1016/j.bone.2016.04.027, PubMed 27142587

Paschalis EP, Gamsjaeger S, Hassler N, Fahrleitner-Pammer A, Dobnig H, Stepan JJ, Pavo I, Eriksen EF, Klaushofer K (2016)
Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality
Bone, 95, 41-46
DOI 10.1016/j.bone.2016.11.002, PubMed 27826025

Simonsen CS, Celius EG, Brunborg C, Tallaksen C, Eriksen EF, Holmøy T, Moen SM (2016)
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
BMC Neurol, 16 (1), 252
DOI 10.1186/s12883-016-0771-4, PubMed 27919248

Aasarød KM, Ramezanzadehkoldeh M, Shabestari M, Mosti MP, Stunes AK, Reseland JE, Beisvag V, Eriksen EF, Sandvik AK, Erben RG, Schüler C, Boyce M, Skallerud BH, Syversen U, Fossmark R (2016)
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice
J Endocrinol, 230 (2), 251-62
DOI 10.1530/JOE-16-0017, PubMed 27325243

Publications 2015

Eriksen EF (2015)
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates]
Tidsskr Nor Laegeforen, 135 (10), 921
DOI 10.4045/tidsskr.15.0521, PubMed 26037748

Eriksen EF (2015)
Treatment of bone marrow lesions (bone marrow edema)
Bonekey Rep, 4, 755
DOI 10.1038/bonekey.2015.124, PubMed 26644910

Paschalis EP, Fratzl P, Gamsjaeger S, Hassler N, Brozek W, Eriksen EF, Rauch F, Glorieux FH, Shane E, Dempster D, Cohen A, Recker R, Klaushofer K (2015)
Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years
J Bone Miner Res, 31 (2), 347-57
DOI 10.1002/jbmr.2696, PubMed 26308158

Shigdel R, Osima M, Ahmed LA, Joakimsen RM, Eriksen EF, Zebaze R, Bjørnerem Å (2015)
Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures
Bone, 81, 1-6
DOI 10.1016/j.bone.2015.06.016, PubMed 26112819

Shigdel R, Osima M, Lukic M, Ahmed LA, Joakimsen RM, Eriksen EF, Bjørnerem Å (2015)
Determinants of Transitional Zone Area and Porosity of the Proximal Femur Quantified In Vivo in Postmenopausal Women
J Bone Miner Res, 31 (4), 758-66
DOI 10.1002/jbmr.2751, PubMed 26588794

Aass C, Norheim I, Eriksen EF, Thorsby PM, Pepaj M (2015)
Single unit filter-aided method for fast proteomic analysis of tear fluid
Anal Biochem, 480, 1-5
DOI 10.1016/j.ab.2015.04.002, PubMed 25862084

Publications 2014

Dahl K, Ahmed LA, Joakimsen RM, Jørgensen L, Eggen AE, Eriksen EF, Bjørnerem Å (2014)
High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study
Bone, 72, 65-70
DOI 10.1016/j.bone.2014.11.012, PubMed 25460573

Eriksen EF (2014)
Commentary on sclerostin deficiency is linked to altered bone composition
J Bone Miner Res, 29 (10), 2141-3
DOI 10.1002/jbmr.2346, PubMed 25158054

Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014)
Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis
Bone, 67, 246-56
DOI 10.1016/j.bone.2014.07.014, PubMed 25053463

Wekre LL, Kjensli A, Aasand K, Falch JA, Eriksen EF (2014)
Spinal deformities and lung function in adults with osteogenesis imperfecta
Clin Respir J, 8 (4), 437-43
DOI 10.1111/crj.12092, PubMed 24308436

Publications 2013

Eriksen EF, Díez-Pérez A, Boonen S (2013)
Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review
Bone, 58, 126-35
DOI 10.1016/j.bone.2013.09.023, PubMed 24120384

Eriksen EF, Halse J, Moen MH (2013)
New developments in the treatment of osteoporosis
Acta Obstet Gynecol Scand, 92 (6), 620-36
DOI 10.1111/j.1600-0412.2012.01473.x, PubMed 22646526

Hammerstad SS, Norheim I, Paulsen T, Amlie LM, Eriksen EF (2013)
Excessive decrease in serum magnesium after total thyroidectomy for Graves' disease is related to development of permanent hypocalcemia
World J Surg, 37 (2), 369-75
DOI 10.1007/s00268-012-1843-2, PubMed 23188529

Hewitt S, Søvik TT, Aasheim ET, Kristinsson J, Jahnsen J, Birketvedt GS, Bøhmer T, Eriksen EF, Mala T (2013)
Secondary hyperparathyroidism, vitamin D sufficiency, and serum calcium 5 years after gastric bypass and duodenal switch
Obes Surg, 23 (3), 384-90
DOI 10.1007/s11695-012-0772-3, PubMed 23015268

Misof BM, Roschger P, Gabriel D, Paschalis EP, Eriksen EF, Recker RR, Gasser JA, Klaushofer K (2013)
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
J Bone Miner Res, 28 (3), 442-8
DOI 10.1002/jbmr.1780, PubMed 23044788

Wium C, Gulseth HL, Eriksen EF, Birkeland KI (2013)
Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes
PLoS One, 8 (12), e83983
DOI 10.1371/journal.pone.0083983, PubMed 24391858

Publications 2012

Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012)
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective
J Bone Miner Res, 27 (5), 963-74
DOI 10.1002/jbmr.1570, PubMed 22467094

Eriksen EF (2012)
Treatment of osteopenia
Rev Endocr Metab Disord, 13 (3), 209-23
DOI 10.1007/s11154-011-9187-z, PubMed 21710179

Eriksen EF, Halse J (2012)
[When should bisphosphonate treatment be discontinued?]
Tidsskr Nor Laegeforen, 132 (14), 1630-2
DOI 10.4045/tidsskr.11.0788, PubMed 22875131

Moen SM, Celius EG, Sandvik L, Brustad M, Nordsletten L, Eriksen EF, Holmøy T (2012)
Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
PLoS One, 7 (9), e45703
DOI 10.1371/journal.pone.0045703, PubMed 23029191

Publications 2011

Bøhmer T, Eriksen EF (2011)
[Something to learn from--something to learn more from?]
Tidsskr Nor Laegeforen, 131 (22), 2221; author reply 2221
DOI 10.4045/tidsskr.11.0657, PubMed 22085940

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011)
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
J Bone Miner Res, 26 (3), 503-11
DOI 10.1002/jbmr.238, PubMed 20814967

Eriksen EF, Ringe JD (2011)
Bone marrow lesions: a universal bone response to injury?
Rheumatol Int, 32 (3), 575-84
DOI 10.1007/s00296-011-2141-2, PubMed 21901347

Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP (2011)
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
J Bone Miner Res, 26 (1), 12-8
DOI 10.1002/jbmr.180, PubMed 20645415

Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U (2011)
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
BMC Endocr Disord, 11, 11
DOI 10.1186/1472-6823-11-11, PubMed 21615901

Syversen U, Halse JI, Geisler J, Eriksen EF (2011)
[Denosumab for treatment of postmenopausal osteoporosis]
Tidsskr Nor Laegeforen, 131 (19), 1893-6
DOI 10.4045/tidsskr.10.1116, PubMed 21984295

Wekre LL, Eriksen EF, Falch JA (2011)
Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta
Arch Osteoporos, 6, 31-8
DOI 10.1007/s11657-011-0054-z, PubMed 22207876

Publications 2010

Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010)
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older
J Am Geriatr Soc, 58 (2), 292-9
DOI 10.1111/j.1532-5415.2009.02673.x, PubMed 20070415

Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010)
Potential mediators of the mortality reduction with zoledronic acid after hip fracture
J Bone Miner Res, 25 (1), 91-7
DOI 10.1359/jbmr.090704, PubMed 19580467

Eriksen EF (2010)
Cellular mechanisms of bone remodeling
Rev Endocr Metab Disord, 11 (4), 219-27
DOI 10.1007/s11154-010-9153-1, PubMed 21188536

Publications 2009

Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, HORIZON-PFT Research Group (2009)
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis
J Bone Miner Res, 24 (9), 1544-51
DOI 10.1359/jbmr.090310, PubMed 19338427

Eriksen EF (2009)
[Osteonecrosis of the jaw]
Ugeskr Laeger, 171 (8), 629; author reply 629
PubMed 19291862

Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009)
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture
J Bone Miner Res, 24 (7), 1308-13
DOI 10.1359/jbmr.090209, PubMed 19257818

Publications 2008

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008)
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Kidney Int, 74 (5), 641-8
DOI 10.1038/ki.2008.193, PubMed 18509324

Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group (2008)
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial
J Am Dent Assoc, 139 (1), 32-40
DOI 10.14219/jada.archive.2008.0017, PubMed 18167382

Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008)
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
J Bone Miner Res, 23 (1), 6-16
DOI 10.1359/jbmr.070906, PubMed 17892374

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Bone, 42 (5), 841-7
DOI 10.1016/j.bone.2008.01.003, PubMed 18314405

Publications 2007

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
N Engl J Med, 356 (18), 1809-22
DOI 10.1056/NEJMoa067312, PubMed 17476007

Eriksen EF, Eghbali-Fatourechi GZ, Khosla S (2007)
Remodeling and vascular spaces in bone
J Bone Miner Res, 22 (1), 1-6
DOI 10.1359/jbmr.060910, PubMed 17040170

Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR (2007)
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
J Bone Miner Res, 22 (1), 142-8
DOI 10.1359/jbmr.061001, PubMed 17032148

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
N Engl J Med, 357 (18), 1799-809
DOI 10.1056/NEJMoa074941, PubMed 17878149

Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA (2007)
Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006
Crit Rev Oncol Hematol, 62 (2), 148-52
DOI 10.1016/j.critrevonc.2006.12.005, PubMed 17336086

Publications 2006

Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006)
Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
J Bone Miner Res, 21 (6), 855-64
DOI 10.1359/jbmr.060314, PubMed 16753016

Publications 2005

Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
J Bone Miner Res, 20 (7), 1244-53
DOI 10.1359/JBMR.050309, PubMed 15940379

Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L (2005)
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study
J Bone Miner Res, 20 (9), 1548-61
DOI 10.1359/JBMR.050411, PubMed 16059627

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005)
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial
J Bone Miner Res, 20 (11), 1905-11
DOI 10.1359/JBMR.050714, PubMed 16234962

Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005)
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
J Clin Endocrinol Metab, 90 (7), 3970-7
DOI 10.1210/jc.2003-1703, PubMed 15840739

McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
Arch Intern Med, 165 (15), 1762-8
DOI 10.1001/archinte.165.15.1762, PubMed 16087825

Paschalis EP, Glass EV, Donley DW, Eriksen EF (2005)
Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial
J Clin Endocrinol Metab, 90 (8), 4644-9
DOI 10.1210/jc.2004-2489, PubMed 15914535

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005)
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women
Bone, 36 (6), 948-58
DOI 10.1016/j.bone.2005.03.003, PubMed 15878318

Publications 2004

Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L (2004)
Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma
Haematologica, 89 (5), 567-77
PubMed 15136220

Eriksen EF, Robins DA (2004)
Teriparatide: A bone formation treatment for osteoporosis
Drugs Today (Barc), 40 (11), 935-48
DOI 10.1358/dot.2004.40.11.872582, PubMed 15645006

Glerup H, Eriksen EF (2004)
[D-vitamin: old paradoxes and new perspectives]
Ugeskr Laeger, 166 (1-2), 36-40
PubMed 14752991

Lind PM, Eriksen EF, Lind L, Orberg J, Sahlin L (2004)
Estrogen supplementation modulates effects of the endocrine disrupting pollutant PCB126 in rat bone and uterus: diverging effects in ovariectomized and intact animals
Toxicology, 199 (2-3), 129-36
DOI 10.1016/j.tox.2004.02.022, PubMed 15147787

Publications 2003

Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L (2003)
Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy
Br J Haematol, 120 (2), 235-42
DOI 10.1046/j.1365-2141.2003.04050.x, PubMed 12542480

Andersen H, Jensen ON, Moiseeva EP, Eriksen EF (2003)
A proteome study of secreted prostatic factors affecting osteoblastic activity: galectin-1 is involved in differentiation of human bone marrow stromal cells
J Bone Miner Res, 18 (2), 195-203
DOI 10.1359/jbmr.2003.18.2.195, PubMed 12568396

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003)
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
J Bone Miner Res, 18 (11), 1932-41
DOI 10.1359/jbmr.2003.18.11.1932, PubMed 14606504

Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF (2003)
Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis
Bone, 32 (3), 297-310
DOI 10.1016/s8756-3282(02)00971-7, PubMed 12667558

Publications 2002

Eriksen EF (2002)
Primary hyperparathyroidism: lessons from bone histomorphometry
J Bone Miner Res, 17 Suppl 2, N95-7
PubMed 12412784

Eriksen EF, Glerup H (2002)
Vitamin D deficiency and aging: implications for general health and osteoporosis
Biogerontology, 3 (1-2), 73-7
DOI 10.1023/a:1015263514765, PubMed 12014847

Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF (2002)
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures
J Bone Miner Res, 17 (7), 1245-55
DOI 10.1359/jbmr.2002.17.7.1245, PubMed 12096838

Publications 2001

Jørgensen NR, Henriksen Z, Sørensen OH, Eriksen EF, Civitelli R, Steinberg TH (2001)
Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors
J Biol Chem, 277 (9), 7574-80
DOI 10.1074/jbc.M104608200, PubMed 11756404

Page visits: 3840